TARDBP and proteostasis deficiencies: Supporting this as a possible therapeutic target, an antibody targeting the RRM1 domain has shown to reduce TDP-43 proteinopathy, cognitive impairment, motor defects and neuroinflammation in a TDP-43 ALS mouse model [173].